Acrivon Therapeutics (ACRV) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 17, 2026, to be held virtually, allowing electronic voting and Q&A for shareholders.

• Shareholders will vote on electing two Class I directors for three-year terms and ratifying the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026.

• The board consists of eight directors divided into three classes with staggered terms, and the majority are independent under Nasdaq rules.

• Proxy materials and the 2025 Annual Report are available online, with options for shareholders to request paper copies.

Voting matters and shareholder proposals

• Proposal 1: Elect Michael Tomsicek and Charles Baum as Class I directors for terms expiring in 2029.

• Proposal 2: Ratify PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026.

• The board recommends voting FOR all nominees and the auditor ratification.

• No other proposals are anticipated, but proxies confer discretionary authority for other matters.

Board of directors and corporate governance

• The board is led by the CEO, who also serves as chairman, with strong independent oversight.

• Committees include audit, compensation, and nominating/governance, all composed of independent directors.

• Directors are evaluated for relevant expertise, diversity, and commitment to shareholder interests.

• A code of business conduct and ethics and insider trading policy are in place.

• Shareholders can communicate directly with the board via established procedures.